Nicotine composition, nebulized liquid, nebulizing device and buccal product
By adding active ingredients and muscarinic receptor agonists to the nicotine composition, an enhanced neural excitation signal is generated synergistically, solving the problem of decreased satisfaction in low-nicotine products and achieving a similar user experience to high-nicotine products at low concentrations.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-30
- Publication Date
- 2026-03-13
AI Technical Summary
Existing low-nicotine products, after reducing nicotine content, show a significant decrease in users' subjective satisfaction, making them difficult for users to accept.
By adding active ingredients and muscarinic receptor agonists, such as nicotine and clobetacholine, to nicotine compositions, a synergistic effect is achieved to generate enhanced parasympathetic nerve excitation signals, supplementing and amplifying peripheral cholinergic signals, and indirectly enhancing the central perception quality of nicotine reward.
Despite a significant reduction in nicotine content, it still provides a level of subjective satisfaction comparable to high-nicotine products, meeting user needs.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This application relates to the field of tobacco alternative technology, specifically to a nicotine composition, atomizing liquid, atomizing device, and oral product. Background Technology
[0002] Currently, products are available on the market designed to replace traditional tobacco products and alleviate nicotine cravings to help smokers quit. For health reasons, developing low-nicotine products is a current research hotspot. However, simply reducing the nicotine content of nicotine products directly reduces the user's subjective satisfaction, and this lack of satisfaction inevitably makes low-nicotine products unacceptable to users.
[0003] Therefore, how to ensure a low nicotine content while also guaranteeing the user's experience has become a pressing technical issue. Summary of the Invention
[0004] This application provides a nicotine composition, atomizing liquid, atomizing device, and oral product to address the issue that reducing nicotine content directly reduces the user's subjective satisfaction.
[0005] This application provides a nicotine composition comprising: an active component and a muscarinic receptor agonist; wherein the active component comprises at least one of the following: nicotine and a nicotine derivative.
[0006] In some embodiments, the weight ratio of the active component to the muscarinic receptor agonist is 5:1 to 50:1.
[0007] In some embodiments, the nicotine derivative includes at least one of the following: nicotine tartrate, nicotine salicylate, nicotine lactate, nicotine benzoate, nicotine levulinate; and / or, the muscarinic receptor agonist includes at least one of the following: clobecholine, clobecholine derivatives.
[0008] This application also provides an atomizing liquid comprising a nicotine composition.
[0009] In some embodiments, the atomizing liquid further includes a solvent, a first flavoring agent, a first seasoning agent, and a first pH adjuster; wherein the solvent includes at least one of vegetable glycerin, propylene glycol, and water; and / or, the first seasoning agent includes at least one of a first cooling agent and a first sweetener; and / or, the first pH adjuster includes at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate; and / or, by weight, the atomizing liquid includes 0.3 to 3 parts of the active ingredient, 0.05 to 0.5 parts of a muscarinic receptor agonist, 80 to 90 parts of the solvent, 1 to 5 parts of the first flavoring agent, 1 to 5 parts of the first seasoning agent, and 0.1 to 0.5 parts of the first pH adjuster.
[0010] This application also provides an atomizing device, which includes an atomizing liquid.
[0011] This application also provides a mouth-holding article comprising a nicotine composition.
[0012] In some embodiments, the oral article further includes a saliva-permeable material, and the oral article includes at least one oral article unit; in each oral article unit, the nicotine composition is encapsulated within the saliva-permeable material.
[0013] In some embodiments, each oral product unit comprises 0.5 mg to 10 mg of the active ingredient and 0.1 mg to 5 mg of a muscarinic receptor agonist; and / or, the nicotine composition further comprises excipients, binders, a second flavoring, a second taster, and a second pH adjuster.
[0014] In some embodiments, the excipient comprises at least one of plant fiber, sugar alcohol, and microcrystalline cellulose; and / or, the binder comprises at least one of hydroxypropyl cellulose, xanthan gum, and povidone; and / or, the second flavoring agent comprises at least one of a cooling agent and a sweetener; and / or, the second pH adjuster comprises at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate; and / or, by weight, the nicotine composition comprises 1-20 parts of the active ingredient, 10-20 parts of the binder, 0.2-10 parts of a muscarinic receptor agonist, 70-80 parts of the excipient, 1-5 parts of the second flavoring, 1-5 parts of the second flavoring agent, and 0.1-0.5 parts of the second pH adjuster.
[0015] This invention provides a nicotine composition comprising an active ingredient and a muscarinic receptor agonist. Through the synergistic effect of the active ingredient and the muscarinic receptor agonist, an enhancement effect far exceeding the arithmetic sum of the individual effects of each component is produced. Even with significantly reduced nicotine content, this composition still provides a level of subjective satisfaction comparable to traditional high-nicotine products, offering a novel and non-obvious technical path for developing popular low-harm nicotine products. Detailed Implementation
[0016] The present invention will be further described in detail below through specific embodiments. Similar elements in different embodiments are referred to by associated similar element reference numerals. In the following embodiments, many details are described to facilitate a better understanding of this application. However, those skilled in the art will readily recognize that some features may be omitted in different situations, or may be replaced by other elements, materials, or methods. In some cases, certain operations related to this application are not shown or described in the specification. This is to avoid obscuring the core parts of this application with excessive description. For those skilled in the art, detailed description of these related operations is not necessary; they can fully understand the related operations based on the description in the specification and general technical knowledge in the art.
[0017] Furthermore, the features, operations, or characteristics described in the specification can be combined in any suitable manner to form various embodiments. At the same time, the steps or actions in the method description can be rearranged or adjusted in a manner obvious to those skilled in the art. Therefore, the various orders in the specification are only for clearly describing a particular embodiment and do not imply a necessary order, unless otherwise stated that a particular order must be followed.
[0018] The serial numbers assigned to components in this document, such as "first" and "second," are used only to distinguish the described objects and have no sequential or technical meaning. The terms "connection" and "linkage" used in this application, unless otherwise specified, include both direct and indirect connections (linkages).
[0019] This application provides a nicotine composition comprising: an active component and a muscarinic receptor agonist; in some embodiments, the active component comprises at least one of the following: nicotine and a nicotine derivative.
[0020] Through the synergistic effect of the active ingredient and the muscarinic receptor agonist, an enhancement effect far exceeding the arithmetic sum of the individual effects of each component is produced. Even with a significant reduction in nicotine content, the composition can still provide subjective satisfaction comparable to products with high nicotine content, providing a novel and non-obvious technical path for developing popular low-harm nicotine products.
[0021] In some embodiments, muscarinic receptor agonists include at least one of the following: clobecholine, clobecholine derivatives (e.g., chloride salts of clobecholine).
[0022] Clobeticolane cannot cross the blood-brain barrier and specifically activates muscarinic receptors only within the peripheral nervous system (PNS). Furthermore, nicotine also produces some cholinergic signals in the peripheral system, but these signals may be incomplete. The addition of clobeticolane can supplement and amplify this peripheral cholinergic signal, thereby generating a stronger and more complete parasympathetic excitation signal.
[0023] This enhanced parasympathetic excitation signal is fed back to the central nervous system via afferent nerves (such as the vagus nerve). The brain integrates this peripheral "physiological confirmation" signal with the "core reward" signal directly triggered by nicotine in the central nervous system. When the two signals are highly synchronized and coordinated, the brain interprets it as a more complete and intense overall sense of satisfaction. Therefore, clobecholine indirectly but significantly enhances the perceived quality of nicotine reward in the central nervous system by optimizing peripheral physiological feedback. In some embodiments, the nicotine derivative can be a derivative obtained by chemically modifying the nicotine nucleus. In some embodiments, the nicotine derivative includes at least one of the following: nicotine tartrate, nicotine salicylate, nicotine lactate, nicotine benzoate, nicotine levulinate, and 6-methylnicotine.
[0024] In some embodiments, the weight ratio of the active component to the muscarinic receptor agonist is 5:1 to 50:1, which ensures the synergistic effect of the nicotine composition.
[0025] For example, the weight ratio of the active ingredient to the muscarinic receptor agonist is 5:1, 10:1, 30:1, 50:1, or any value within the above range.
[0026] This application also provides an atomizing liquid comprising the nicotine composition described in any of the above embodiments.
[0027] In some embodiments, the atomizing liquid further includes a solvent, a first flavoring agent, a first taste agent, and a first pH adjuster. This composition ensures both the functional requirements of the atomizing liquid and the ability to produce a strong sense of satisfaction even at low concentrations of nicotine.
[0028] In some embodiments, the solvent includes at least one of vegetable glycerin, propylene glycol, and water.
[0029] In some embodiments, the first flavoring agent includes at least one of a first cooling agent and a first sweetener.
[0030] For example, the first sweetener includes at least one of the following: xylitol, sorbitol, mannitol, iodine, lactitol, maltitol, isomaltitol, hydrogenated starch hydrolysate, erythritol, maltotriol, aspartame, acesulfame potassium, sodium saccharin, sucralose, neotame, cyclamate, alitane, steviol glycosides, arabinitol, and monk fruit sweetener.
[0031] For example, the first cooling agent includes at least one of the following: menthol, menthol derivatives, WS-3, and WS-23.
[0032] In some embodiments, the first pH adjuster includes at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate.
[0033] In some embodiments, the first flavoring includes at least one selected from bergamot flavoring, eucalyptus flavoring, citrus flavoring, lemon flavoring, peppermint flavoring, peppermint flavoring, menthol, licorice flavoring, wintergreen flavoring, tobacco flavoring, coffee flavoring, vanilla flavoring, lime flavoring, apple flavoring, peach flavoring, mango flavoring, cherry flavoring, blueberry flavoring, strawberry flavoring, cola flavoring, cinnamon flavoring, pandan flavoring, and watermelon flavoring.
[0034] In some embodiments, the atomizing liquid comprises, by weight, 0.3 to 3 parts of active ingredient, 0.05 to 0.5 parts of muscarinic receptor agonist, 80 to 90 parts of solvent, 1 to 5 parts of first flavoring, 1 to 5 parts of first flavoring agent, and 0.1 to 0.5 parts of first pH adjuster.
[0035] For example, by mass, the atomizing liquid includes 1 to 2 parts of active ingredient, 0.1 to 0.4 parts of muscarinic receptor agonist, 82 to 88 parts of solvent, 2 to 4 parts of first flavoring, 2 to 4 parts of first flavoring agent, and 0.2 to 0.4 parts of first pH adjuster.
[0036] This application also provides an atomizing device, which includes: a liquid storage tank, a liquid guiding material, and an atomizing element; wherein, the liquid guiding material transports the atomizing liquid in the liquid storage tank to the atomizing element, and the atomizing element performs atomization treatment on the atomizing liquid.
[0037] In some embodiments, the atomizing fluid may be a water-based atomizing fluid or an atomizing fluid using glycerol, propylene glycol, or other solvents as solvents.
[0038] In some embodiments, the atomizing device may be a battery-free atomizer or a battery-equipped atomizer.
[0039] This application also provides a mouth-sucking article comprising a nicotine composition.
[0040] In some embodiments, the oral product is in the form of an oral film. In some embodiments, the oral product further includes a film-forming agent, and the oral product as a whole is in the form of a film sheet.
[0041] In some embodiments, the oral article is in the form of an oral film including a support layer. In some embodiments, the nicotine composition is loaded onto the support layer, or the nicotine composition may be sandwiched in the support layer. In some embodiments, the support layer is a water-permeable nonwoven fabric.
[0042] In some embodiments, the oral article is a chewable tablet, i.e., in the form of chewing gum, and the oral article further includes a gum base carrier on which the nicotine composition is loaded.
[0043] In some embodiments, the oral article is an oral tablet, and in some embodiments, the oral tablet is disintegratable or soluble in the oral cavity.
[0044] In some embodiments, the oral article is a pouch article, which further includes a saliva-permeable material, and the oral article includes at least one oral article unit; in each oral article unit, the nicotine composition is encapsulated within the saliva-permeable material.
[0045] In some embodiments, each oral product unit, i.e., an oral bag weighing approximately 4.9 to 5.1 g, contains 0.5 mg to 10 mg of the active ingredient and 0.1 mg to 5 mg of a muscarinic receptor agonist. This content satisfies both the functional requirements of the product and the requirements of market management.
[0046] For example, the content of the active ingredient in each oral product unit is 0.5 mg, 3 mg, 6 mg, 8 mg, 10 mg or any value within the above range; the content of the muscarinic receptor agonist in each oral product unit is 0.1 mg, 1 mg, 3 mg, 5 mg or any value within the above range.
[0047] In some embodiments, the nicotine composition further includes excipients, binders, a second flavoring, a second taste agent, and a second pH adjuster.
[0048] In some embodiments, the excipients include at least one of plant fiber, sugar alcohol, and microcrystalline cellulose.
[0049] In some embodiments, the adhesive includes at least one of hydroxypropyl cellulose, xanthan gum, and povidone.
[0050] In some embodiments, the second flavoring includes at least one of bergamot flavoring, eucalyptus flavoring, citrus flavoring, lemon flavoring, peppermint flavoring, peppermint flavoring, menthol, licorice flavoring, wintergreen flavoring, tobacco flavoring, coffee flavoring, vanilla flavoring, lime flavoring, apple flavoring, peach flavoring, mango flavoring, cherry flavoring, blueberry flavoring, strawberry flavoring, cola flavoring, cinnamon flavoring, pandan flavoring, and watermelon flavoring.
[0051] In some embodiments, the second flavoring agent includes at least one of a second cooling agent and a second sweetener.
[0052] For example, the second sweetener includes at least one of the following: xylitol, sorbitol, mannitol, iodine, lactitol, maltitol, isomaltitol, hydrogenated starch hydrolysate, erythritol, maltotriol, aspartame, acesulfame potassium, sodium saccharin, sucralose, neotame, cyclamate, alitane, steviol glycosides, arabinitol, and monk fruit sweetener.
[0053] For example, the second cooling agent includes at least one of the following: menthol, menthol derivatives, WS-3 and WS-23.
[0054] In some embodiments, the second pH adjuster includes at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate.
[0055] In some embodiments, the nicotine composition comprises, by weight, 1 to 20 parts of an active ingredient, 10 to 20 parts of a binder, 0.2 to 10 parts of a muscarinic receptor agonist, 70 to 80 parts of an excipient, 1 to 5 parts of a second flavoring, 1 to 5 parts of a second flavoring agent, and 0.1 to 0.5 parts of a second pH adjuster.
[0056] For example, by weight, a nicotine composition includes 5 to 15 parts of active ingredient, 13 to 16 parts of binder, 3 to 7 parts of muscarinic receptor agonist, 73 to 77 parts of excipient, 2 to 4 parts of secondary flavoring, 2 to 4 parts of secondary flavoring agent, and 0.2 to 0.3 parts of secondary pH adjuster.
[0057] This application also provides a method for preparing an atomizing fluid, comprising: 1. Add the active component and muscarinic receptor agonist to the solvent and stir to obtain a homogeneous mixture.
[0058] 2. Add the first flavoring agent, the first fragrance and the first pH adjuster to the mixture, stir and degas to obtain the atomized liquid.
[0059] In some embodiments, the atomizing liquid comprises, by weight, 0.3 to 3 parts of active ingredient, 0.05 to 0.5 parts of muscarinic receptor agonist, 80 to 90 parts of solvent, 1 to 5 parts of first flavoring, 1 to 5 parts of first flavoring agent, and 0.1 to 0.5 parts of first pH adjuster.
[0060] For example, by mass, the atomizing liquid includes 1-2 parts of active substance, 0.1-0.4 parts of muscarinic receptor agonist, 82-88 parts of solvent, 2-4 parts of primary flavoring agent, 2-4 parts of primary flavoring agent, and 0.2-0.4 parts of primary pH adjuster.
[0061] This application also provides a method for preparing a mouth bag, comprising: 1. Dry mix the excipients, active ingredients, and muscarinic receptor agonists to obtain a mixture.
[0062] 2. Spray an aqueous solution of binder, second pH adjuster, second flavoring agent and second seasoning agent into the mixture, and obtain wet granules by wet granulation.
[0063] In some embodiments, the filler in the oral pouch, by weight, comprises: 1 to 20 parts of active ingredient, 10 to 20 parts of binder, 0.2 to 10 parts of muscarinic receptor agonist, 70 to 80 parts of excipient, 1 to 5 parts of second flavoring, 1 to 5 parts of second flavoring agent, and 0.1 to 0.5 parts of second pH adjuster.
[0064] For example, by mass, the filling in the oral pouch includes: 5-15 parts of active ingredient, 13-16 parts of binder, 3-7 parts of muscarinic receptor agonist, 73-77 parts of excipient, 2-4 parts of secondary flavoring, 2-4 parts of secondary flavoring agent, and 0.2-0.3 parts of secondary pH adjuster.
[0065] In some embodiments, wet particles are obtained through a 40-mesh sieve.
[0066] 3. After drying the prepared wet granules, fill them into a saliva-permeable material bag to obtain a mouth bag.
[0067] In some embodiments, the drying conditions include: a drying temperature of 48-52°C, a drying time of 1.5-2.5 hours, and a moisture content of <5wt% for the dried particles.
[0068] Specifically, the drying temperature is 48℃, 50℃, 52℃ or any value within the above range, the drying time is 1.5 hours, 2 hours, 2.5 hours or any value within the above range, and the moisture content of the dried particles is 2wt%, 3wt%, 5wt% or any value within the above range. Specific Implementation To verify the synergistic effect of the nicotine composition in this application, examples and comparative examples are provided below.
[0070] Example 1 1. Add the active components nicotine and muscarinic receptor agonist clobetacholine chloride to propylene glycol and glycerin, and obtain a homogeneous mixture by stirring.
[0071] 2. Add the first flavoring agent (sweetener sucralose), the first flavoring menthol, and the first pH adjuster benzoic acid to the mixture, stir and degas to obtain the atomized liquid.
[0072] The dosage of each component in the atomizing fluid is shown in Table 1.
[0073] Comparative Example 1 The difference from Example 1 is that no clobetacholine chloride was added, and the amount of nicotine used was higher than that in Example 1. The specific amount is shown in Table 1.
[0074] Comparative Example 2 The difference from Example 1 is that chlorobenzylcholine chloride was not added.
[0075] Comparative Example 3 The difference from Example 1 is that no nicotine was added.
[0076] The nebulized liquids prepared in Example 1 and Comparative Examples 1-3 were obtained and added to a refillable nebulizer. The following tests were conducted to evaluate the results: Experienced nicotine users were recruited to use the nebulizer and the pod on different test days. Subjective evaluations of "satisfaction" (1-10 points), "reduction in craving" (percentage), and "throat hit" (1-5 points) were performed and averaged. The test data are shown in Table 3.
[0077] Example 2 1. Dry mix the excipient microcrystalline cellulose, the active component nicotine, and the muscarinic receptor agonist clobetacholine chloride to obtain a mixture.
[0078] 2. Spray an aqueous solution of binder hydroxypropyl cellulose, second pH adjuster sodium bicarbonate and citric acid, second flavoring mint flavor and second flavoring agent (sweetener sucralose) into the mixture, and obtain wet granules by wet granulation.
[0079] The wet particles are obtained by passing them through a 40-mesh sieve.
[0080] 3. After drying the prepared wet granules, fill them into a saliva-permeable material bag to obtain a mouth bag.
[0081] The drying conditions include: a drying temperature of 50°C, a drying time of 2 hours, and a moisture content of 3 wt% for the dried particles.
[0082] The components and their contents in the oral bag are detailed in Table 2.
[0083] Comparative Example 4 The difference from Example 2 is that chlorobenzylcholine chloride was not added.
[0084] Comparative Example 5 The difference from Example 2 is that no clobetacholine chloride was added, and the amount of nicotine used was higher than that in Example 2. The specific amount is shown in Table 2.
[0085] Experienced nicotine users were recruited to use the nicotine pouch on different test days. Subjective assessments of "satisfaction" (1-10 points), "reduction in craving" (percentage), and "throat hit" (1-5 points) were conducted and averaged. The test data are shown in Table 4.
[0086] Table 1. Component content of four types of atomizing fluids
[0087] Table 2. Component Content in Oral Bags
[0088] Table 3 Test Data for Atomizing Equipment
[0089] Table 4. Test data for the mouth-held bag.
[0090] As can be seen from Table 3, the scores of the atomizing device in the example are significantly higher than those of the control group with the same nicotine level (Comparative Example 2), and the effect is comparable to that of the high nicotine control group (Comparative Example 1), proving that it can provide almost the same sense of satisfaction when the nicotine content is reduced by two-thirds.
[0091] Similarly, as shown in Table 4, the scores of all items corresponding to the oral bag in the example were significantly higher than those of the control group with the same nicotine content (Comparative Example 4), and the effect was comparable to that of the high nicotine control group (Comparative Example 5), proving that almost the same sense of satisfaction could be provided when the nicotine content was reduced by half.
[0092] Finally, it should be noted that in this document, relational terms such as "first" and "second" are used only to distinguish one entity or operation from another, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Furthermore, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Without further limitations, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes said element.
[0093] The above examples illustrate the present invention only to aid in understanding it and are not intended to limit the scope of the invention. Those skilled in the art can make various simple deductions, modifications, or substitutions based on the principles of this invention.
Claims
1. A nicotine composition, characterized in that, The nicotine composition comprises: an active ingredient and a muscarinic receptor agonist; The active ingredient includes at least one of the following: nicotine or nicotine derivatives.
2. The nicotine composition according to claim 1, characterized in that, The weight ratio of the active component to the muscarinic receptor agonist is 5:1 to 50:
1.
3. The nicotine composition according to any one of claims 1-2, characterized in that, The nicotine derivatives include at least one of the following: nicotine tartrate, nicotine salicylate, nicotine lactate, nicotine benzoate, nicotine levulinate; and / or, The muscarinic receptor agonist includes at least one of the following: clobecholine or clobecholine derivatives.
4. An atomizing fluid, characterized in that, The atomizing liquid comprises the nicotine composition according to any one of claims 1-3.
5. The atomizing liquid according to claim 4, characterized in that, The atomizing liquid also includes a solvent, a first flavoring agent, a first seasoning agent, and a first pH adjuster; The solvent includes at least one of vegetable glycerin, propylene glycol, and water; and / or, The first flavoring agent includes at least one of a first cooling agent and a first sweetener: and / or, The first pH adjuster includes at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate; and / or, The atomizing liquid comprises, by weight, 0.3 to 3 parts of the active component, 0.05 to 0.5 parts of the muscarinic receptor agonist, 80 to 90 parts of the solvent, 1 to 5 parts of the first flavoring, 1 to 5 parts of the first seasoning agent, and 0.1 to 0.5 parts of the first pH adjuster.
6. An atomizing device, characterized in that, The atomizing device includes the atomizing liquid as described in any one of claims 4-5.
7. An oral product, characterized in that, The oral product comprises the nicotine composition according to any one of claims 1-3.
8. The oral article according to claim 7, characterized in that, The oral article further includes a saliva-permeable material, and the oral article includes at least one oral article unit; in each oral article unit, the nicotine composition is encapsulated within the saliva-permeable material.
9. The oral article according to claim 8, characterized in that, Each sublingual tablet contains 0.5 mg to 10 mg of the active ingredient and 0.1 mg to 5 mg of muscarinic receptor agonist; And / or, The nicotine composition also includes excipients, binders, a second flavoring, a second taste agent, and a second pH adjuster.
10. The oral article according to claim 9, characterized in that, The excipients include at least one of plant fiber, sugar alcohol, and microcrystalline cellulose; and / or, The adhesive comprises at least one of hydroxypropyl cellulose, xanthan gum, and povidone: and / or, The second flavoring agent includes at least one of a cooling agent and a sweetener: and / or, The second pH adjuster includes at least one of benzoic acid, lactic acid, citric acid, sodium bicarbonate, and sodium carbonate; and / or, The nicotine composition comprises, by weight, 1-20 parts of the active ingredient, 10-20 parts of the binder, 0.2-10 parts of the muscarinic receptor agonist, 70-80 parts of the excipient, 1-5 parts of the second flavoring, 1-5 parts of the second flavoring agent, and 0.1-0.5 parts of the second pH adjuster.